MedPath

A Pilot Study to Test the Effect of Treating Depression Associated with Rueumatoid Arthritis (RA) using Venlaflaxine - Venlaflaxine & Numact Study

Conditions
Symptoms of Depression as defined by the Hospital Anxiety and Depression Questionnaire associated with Rheumatoid Arthritis
Registration Number
EUCTR2004-002482-20-GB
Lead Sponsor
ewcastle upon Tyne Hospitals NHS Trust
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
20
Inclusion Criteria

Rheumatoid Arthritis(ACR criteria)
Male or Female Aged 18 years or over.
Female patients of childbearing potential must be using an adequate and reliable method of contraception whilst taking Venlaflaxine.
Willing and able to provide written informed consent.
Functional classification of II or III (ACR criteria)
A score > 10 on the Hospital anxiety and Depression score

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Previously Diagnosed Depression
Other physically disabling condition/concomitant chronic disease
Contraindicated use of Venlaflaxine

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath